•    

All fields are required.

Close Appointment form

Management Team

Improving patient outcomes with innovative drug therapies.

Ajay Gupta, M.D.

Chief Scientific Officer

Ajay Gupta, 59 is the Chief Scientific Officer and has served in that position since he joined the company in June of 2009. Dr. Gupta has been a member of Rockwell’s Scientific Advisory Board since November, 2005. From 2002 to 2009, Dr. Gupta was an Associate Professor of Medicine at UCLA and Charles Drew University Schools of Medicine in Los Angeles where he had an active nephrology practice. Dr. Gupta is the inventor of dialysate iron therapy using Soluble Ferric Pyrophosphate (SFP) as well as the inventor of intravenous (IV) iron therapy using slow continuous infusion of SFP. He has filed a number of patents in the areas of drugs, medical devices and diagnostic tests. Dr. Gupta earned his MBBS degree and completed his residency in Internal Medicine from All India Institute of Medical Sciences (AIIMS), New Delhi. In 1990, he completed a Nephrology Clinical/Research Fellowship from Washington University, St. Louis, Missouri. He has served on the faculty at Washington University, St. Louis; State University of New York, Syracuse; University of Alabama, Birmingham and Henry Ford Hospital, Detroit; MI. Dr. Gupta is the founder and Chairman of the Indian Society for Bone and Mineral Research; earned his MBBS degree and completed his residency in Internal Medicine for AII India Institute of Medical Sciences, New Delhi; has completed a clinical fellowship in Nephrology from Wayne State University, Detroit, Michigan and a research fellowship in Nephrology from Washington University, St. Louis, Missouri.

Raymond D. Pratt, M.D.

Chief Medical Officer

Raymond D. Pratt, M.D, 66, is the Chief Medical Officer since he joined the company in April, 2012. Dr. Pratt was Vice President R&D and as the scientific leader in its Emerging Business and Renal Business Units at Shire PLLC. Previous roles at Shire included Vice President Global Clinical Medicine and Global Clinical Affairs and head of US Clinical Development. Dr. Pratt was instrumental in the FDA approval of Fosrenol ESRD indication and CKD non-dialysis indication in the European Union and United States. He was responsible for three new drug applications as well as multiple EU applications. He has managed ten different drugs through all stages of global development for renal and other indications and has extensive experience appearing before the FDA. Prior to Shire, Dr. Pratt was Senior Director, Clinical Research and Development at Eisai Medical Research from 1994 to 2003, where he was head of Central Nervous System and Internal Medicine clinical development. Dr. Pratt received his M.D. from the University of Illinois College of Medicine and completed his nephrology fellowship at the Walter Reed Army Medical Center and served as the Asst. Chief of Nephrology Services and Director of Dialysis Services. He has served as an Assistant Professor Johns Hopkins University Department of Medicine and Nephrology from 1989 to 1993.